Ann Pharmacol Pharm | Volume 5, Issue 5 | Research Article | Open Access
Hasan K1*, Dede S1, Ali Kemal K2 and Mehmet EY2
1Department of Nephrology, Health Sciences University, Turkey
2Department of Nephrology, Dicle University, Turkey
*Correspondance to: Hasan Kayabasi
Fulltext PDFAim: Oxidative Stress (OS) is a well-defined risk factor of Atherosclerosis (AS) in dialysis patients. We aimed to compare the effects of losartan and nebivolol on the level of OS parameters such as Total Antioxidant Capacity (TAC), erythrocyte Superoxide Dismutase (SOD) and Total Oxidant Status (TOS) in patients receiving Hemodialysis (HD) or Peritoneal Dialysis (PD). Material and method: Eighty patients on PD or HD for at least 6 months without antihypertensive medication and 30 years age and gender-matched healthy volunteers were selected in this study. The patients were and only assigned into two groups; losartan (group I) and nebivolol (group II). Plasma levels of TAC, SOD, and TOS were analyzed. Oxidative Stress Index (OSI) was calculated based on the ratio of TOS level to TAC level (TOS/TAC). Subsequent to the initial evaluation of patients and healthy subjects, losartan 50 mg to 100 mg and nebivolol 5 mg were initiated. Findings: Statistically significant differences were observed between patients and the control group in terms of pro-oxidants (TOS and OSI), and antioxidants (TAC and erythrocyte SOD) (p=0.002, p=0.005, p=0.002, p<0.001; respectively). We detected a significant increase in TAC levels (p<0.001), a decrease in TOS levels, and OSI values (p=0.019, and p<0.001; respectively), and nonsignificant change in SOD levels (p=0.087) in patients receiving nebivolol therapy. At the final evaluation, there was no significant difference between losartan and nebivolol groups in terms of blood pressure or TAC, TOS, OSI, and SOD levels (p=0.574, p=0.696, p=0.586, and p=0.534; respectively). Conclusion: Although the positive effect of nebivolol treatment was more evident, we failed to demonstrate a significant difference between losartan and nebivolol treatments with regard to OS parameters including TAC, TOS, OSI, and erythrocyte SOD.
Hemodialysis; Peritoneal dialysis; Losartan; Nebivolol; Oxidative stress
Hasan K, Dede S, Ali Kemal K, Mehmet EY. Evaluation of Effects of Losartan and Nebivolol on Oxidative Stress Parameters in Dialysis Patients. Ann Pharmacol Pharm. 2020;5(5):1191.